Preparing document for print. Please wait.
State of Ohio - Controlling Board Request
STATE OF OHIO
CONTROLLING BOARD
30 East Broad Street, 34th Floor
Columbus, Ohio 43215-3457
(614) 466-5721 FAX:(614) 466-3813
OPERATING REQUEST Controlling Board No.
DOH0100425
Status:  Approved
Meeting Date:  12/4/2017

GENERAL INFORMATION
Agency
Health


Division/Institution
Health
Waiver of Competitive Selection  (Revised Code Section 127.16B)
      No Competitive Opportunity
      Agency Released Competitive Opportunity
Agency Released Competitive Opportunity (Revised Code Section 127.162)
Other Statutory Authority/Bill Section:
Operating Transfer Request  (Revised Code Section 127.14)
      Appropriation
      Cash
      Other Statutory Authority/Bill Section:
Fiscal Year(s)
2018
Bill No.
HB 49
Eligible for OBM
Director Approval?
No

VENDOR INFORMATION
For FYAmountNameAddressCityStateCountyZip Code
DOH01 2018 $301,425.60 ORASURE TECHNOLOGIES INC Dept 269701 PO Box 67000 Detroit MI 48267

FUNDING INFORMATION
Fund GroupFund CodeAppropriation Line ItemAppropriation Line Item NameFYAmountFYAmount
FED 3920 440618 Federal Public Health Programs 2018 $50,000.00 $.00
GRF GRF 440444 AIDS PREVENTION& TREATMENT 2018 $251,425.60 $.00

SIGNATURES
     
Lance D. Himes, Director 12/04/2017
   
Agency Director or Authorized Agent On The Date Of
   
11/13/2017 Christine Morrison
   
Date Controlling Board President/OBM Director
   
AGENCY CONTACT
Name:  Paul Maragos Title:  Health Planning Admin 3
Phone:  (614) 644 - 6213 Fax:  (614) 752 - 9783 E-Mail:  Paul.Maragos@odh.ohio.gov
REQUIRED EXPLANATION OF REQUEST
  The Ohio Department of Health (ODH) respectfully requests Controlling Board approval for a waiver of competitive selection in the amount of $301,425.60 from fund 3920, ALI 440618 (Fed Public Health Prgms) and Fund GRF, ALI 440444 (AIDS Prevention & Treatment) in FY18 to purchase OraQuick Advance Rapid HIV-1/2 test kits from OraSure Technologies, Inc., Detroit, MI, for the HIV Prevention Program.  
  The HIV Prevention Program is responsible for oversight of HIV testing in funded Counseling, Testing, and Referral (CTR) sites throughout Ohio. There are over 164 sites.

The Centers for Disease Control and Prevention (CDC) provides program funding encouraging the HIV Prevention Program to utilize rapid testing technology to improve the number of testing clients who receive results and who are then connected to medical follow up and care. With conventional testing technologies, nearly 40 percent of clients fail to return for test results.

Per Centers for Disease Control and Prevention (CDC), approximately 40,000 new HIV infections occur each year in the US. One fourth of individuals living with HIV are unaware that they have the virus. An HIV test is the only way to determine if a person is living with the virus. Once an individual knows they are living with HIV they can seek care and practice safer behaviors that may reduce or eliminate the likelihood of infecting others.

Due to the number of Ohioans with HIV who do not know their sero-status and unknowingly pass the HIV virus to others, it is critical that ODH make available testing technologies that are more user-friendly and do not require a return clinic visit for results. In testing sites that utilize the OraQuick rapid test, the demand for testing increased by 10 percent and 99 percent of clients received their results.

Using the OraQuick ADVANCE Rapid HIV-1/2 antibody test kits allows for testing of more individuals due to the following:

1. Quicker results, which eliminates the need for people to return to get their results (results in approx. 20 minutes).
2. People who do not like a needle stick, or otherwise afraid of a blood test, may decide to be tested.
3. If people know they are positive for the HIV virus, they can start to receive treatment sooner and take steps to prevent transmission of the disease.
4. No specialized equipment is required for the testing and the oral fluid can be stored at room temperature.

If the testing kits are not available to the different agencies to perform the testing, many high-risk patients will not be tested.

OraSure Technologies, Inc. is the only licensed manufacturer of the OraQuick Advance Rapid HIV-1/2 test and control.
 
   
Attachments Controlling Board Request No.: DOH0100425
Attachment TypeAttachment Description
Sole source justification letter Vendor Letter
Other Quote
Release and Permit Approved Release and Permit
DOH0100425-01182018112132.PDF Non Substantive Change Request for request DOH0100425
 
Release and Permit Information
NameFYAmountR & P #R & P DateIssued ByComments
ORASURE TECHNOLOGIES INC 2018 $301,425.60 State Purchasing

Operating Request Required Information
Purchases of Supplies or Equipment - ORASURE TECHNOLOGIES INC
Controlling Board Request No.: DOH0100425
1. Identify the supply or supplies/equipment and provide the amount of each item.
   
 
Supply/Equipment NamePrice per UnitNumber of UnitsAmount
1001-0078 kit, oq advance 100 count $1,000.00 299 $299,000.00
1001-10077 Kit, Controls $25.00 20 $500.00
1001-0079 kit, OQ Advance, 25 count $250.00 2 $500.00
503 -50 Kit, Orasure Hiv-1 50 Count $237.60 6 $1,425.60
   
2. 
Cite the account category,  subobject code, and amount of each item included in this purchase from this vendor.
 
ObjectSubobjectAmountNon-Exempt Amount
521057 $301,425.60 $301,425.60
Total Amounts $301,425.60 $301,425.60
   
3.
Selection Process: Was this purchase subject to selection by a Request for Proposal (RFP) or Request for Quote (RFQ) process? No
Explain why this purchase was not subject to an RFP or RFQ process.
OraSure Technologies, Inc., is the only licensed manufacturer of the OraQuick Advance Rapid HIV-1/2 test and control.
   
4. Contractor Procurement Compliance:
a. Is this vendor in compliance with Buy America? Yes
Explain: OraSure is located in MI.
   
b. Is this vendor in compliance with Buy Ohio? No
Explain:OraSure is located in MI.